Security
Q32 Bio Inc. Common Stock · QTTB
QTTBNASDAQCommon stockCurrentCIK 1661998Updated Oct 15, 2026
Name history
Q32 Bio Inc. · through Oct 14, 2026Homology Medicines, Inc. · through Mar 22, 2024
QTTB price & chart
Loading TradingView…
NASDAQ:QTTB on TradingView ↗About the company
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
In the news
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update News provided by Q32 Bio Nov 13, 2025, 06:59 ET Share this article Share to X Share this article Share to X -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patient ↗
Recent filings
4 filing
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A - filed by Sirenia Capital Management LP regarding Q32 Bio Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 57,784,000Source | 104,542,000Source | 115,867,000Source | 66,117,000Source | 124,207,000Source | 63,675,000Source | 79,071,000Source | 152,334,000Source | 61,776,000Source | 92,332,000Source | 84,564,000Source | 228,470,000Source |
| Property, Plant and Equipment, NetUSD | 1,069,000Source | 1,488,000Source | 804,000Source | 1,160,000Source | 1,553,000Source | 889,000Source | 1,251,000Source | 1,659,000Source | 979,000Source | 1,370,000Source | 0Source | 1,078,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 49,039,000Source | 89,078,000Source | 106,270,000Source | 54,832,000Source | 97,661,000Source | 50,751,000Source | 65,483,000Source | 115,509,000Source | 48,297,000Source | 77,965,000Source | 39,266,000Source | 33,986,000Source |
| Assets, CurrentUSD | 50,810,000Source | 93,898,000Source | 109,646,000Source | 58,324,000Source | 111,620,000Source | 57,202,000Source | 68,632,000Source | 138,043,000Source | 55,050,000Source | 81,877,000Source | 83,914,000Source | 181,015,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,771,000Source | 4,820,000Source | 3,376,000Source | 3,492,000Source | 3,973,000Source | 6,451,000Source | 3,149,000Source | 2,731,000Source | 6,753,000Source | 3,912,000Source | 1,001,000Source | 5,989,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,258,000Source | 5,869,000Source | 4,770,000Source | 5,416,000Source | 6,016,000Source | 4,937,000Source | 5,571,000Source | 6,160,000Source | 5,100,000Source | 5,722,000Source | 650,000Source | 20,563,000Source |
| Other Assets, NoncurrentUSD | 0Source | 40,000Source | — | 570,000Source | 1,096,000Source | — | 444,000Source | 1,101,000Source | 0Source | 116,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 76,232,000Source | 86,247,000Source | 9,962,000Source | 78,352,000Source | 90,696,000Source | 17,362,000Source | 83,085,000Source | 103,565,000Source | 19,762,000Source | 86,657,000Source | 11,573,000Source | 50,492,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 6,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 244,273,000Source | 238,919,000Source | 327,450,000Source | 243,097,000Source | 236,540,000Source | 258,913,000Source | 241,829,000Source | 234,824,000Source | 247,005,000Source | 240,487,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -262,723,000Source | -220,625,000Source | -221,548,000Source | -255,334,000Source | -203,030,000Source | -212,602,000Source | -245,845,000Source | -186,052,000Source | -204,993,000Source | -234,814,000Source | -542,098,000Source | -429,137,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | -1,000Source | — | 0Source | -1,000Source | — | 0Source | -5,000Source | — | 0Source | -5,000Source | -404,000Source |
| Stockholders' Equity Attributable to ParentUSD | -18,448,000Source | 18,295,000Source | 105,905,000Source | -12,235,000Source | 33,511,000Source | 46,313,000Source | -4,014,000Source | 48,769,000Source | 42,014,000Source | 5,675,000Source | 72,991,000Source | 177,978,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | — | — | — | — | — | — | 615,088,000Source | 607,513,000Source |
| Liabilities and EquityUSD | 57,784,000Source | 104,542,000Source | 115,867,000Source | 66,117,000Source | 124,207,000Source | 63,675,000Source | 79,071,000Source | 152,334,000Source | 61,776,000Source | 92,332,000Source | 84,564,000Source | 228,470,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,110,000Source | 14,383,000Source | 5,401,000Source | 11,534,000Source | 17,194,000Source | 10,669,000Source | 14,579,000Source | 32,953,000Source | 11,346,000Source | 16,465,000Source | 11,573,000Source | 22,576,000Source |
| Operating Lease, Liability, CurrentUSD | 671,000Source | 1,027,000Source | 735,000Source | 651,000Source | 1,351,000Source | 714,000Source | 631,000Source | 1,560,000Source | 693,000Source | 612,000Source | 1,318,000Source | 1,561,000Source |
| Accounts Payable, CurrentUSD | 973,000Source | 1,258,000Source | 1,565,000Source | 910,000Source | 2,484,000Source | 653,000Source | 2,712,000Source | 4,960,000Source | 879,000Source | 2,989,000Source | 3,234,000Source | 1,144,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,121,000Source | 5,793,000Source | 4,561,000Source | 5,296,000Source | 5,948,000Source | 4,754,000Source | 5,467,000Source | 6,099,000Source | 4,943,000Source | 5,636,000Source | 0Source | 27,916,000Source |
| Other Liabilities, NoncurrentUSD | 55,000,000Source | 55,000,000Source | — | 55,000,000Source | 55,000,000Source | — | 55,000,000Source | 55,113,000Source | 0Source | 55,000,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,905,000Source | 8,912,000Source | 3,836,000Source | 4,396,000Source | 11,020,000Source | 3,777,000Source | 5,265,000Source | 19,825,000Source | 4,232,000Source | 7,479,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,798,000Source | — | — | — |
| Short-term InvestmentsUSD | — | 0Source | — | — | — | — | — | — | — | 0Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -112,961,000Source | -5,005,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,548,000Source | 1,342,000Source | 5,255,000Source | 4,386,000Source | 7,324,000Source | 13,054,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -226,000Source | -277,000Source | -2,110,000Source | -1,043,000Source | 2,090,000Source | -981,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 100,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,343,000Source | -12,482,000Source | -33,543,000Source | -67,715,000Source | -96,230,000Source | -113,661,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 7,000,000Source | 19,925,000Source | 101,326,000Source | 36,716,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 75,000Source | 228,000Source | 1,285,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 8,797,000Source | — | -3,125,000Source | 95,138,000Source | 184,000Source | 596,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | 5,280,000Source | -76,349,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 49,686,000Source | 89,725,000Source | 106,917,000Source | 55,479,000Source | 51,398,000Source | 66,130,000Source | 48,944,000Source | 78,612,000Source | — | 33,986,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,176,000Source | 1,382,000Source | 1,686,000Source | 1,268,000Source | 1,548,000Source | 1,342,000Source | 5,255,000Source | 4,386,000Source | 7,324,000Source | 13,054,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 33,000Source | 48,000Source | 180,000Source | 194,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| DepreciationUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 90,000Source | 119,000Source | 391,000Source | 487,000Source | 578,000Source | 1,293,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | 100,000Source | — | — | 3,800,000Source | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 131,249,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 94,000Source | -49,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | 11,737,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | 8,866,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,022,000Source | 4,468,000Source | 4,859,000Source | 4,010,000Source | 4,504,000Source | 5,104,000Source | 17,679,000Source | 17,959,000Source | 31,256,000Source | 38,138,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -1,625,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 21,000Source | 0Source | 715,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,389,000Source | -17,595,000Source | -8,946,000Source | -9,489,000Source | -7,609,000Source | -11,031,000Source | 29,821,000Source | -47,733,000Source | -112,961,000Source | -5,005,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,389,000Source | -17,595,000Source | -8,946,000Source | -9,489,000Source | -7,609,000Source | -11,031,000Source | 29,821Source | -47,733Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 188,000Source | 1,219,000Source | 172,000Source | -318,000Source | 113,000Source | 1,197,000Source | 12,919,000Source | 20,015,000Source | — | — |
| Operating ExpensesUSD | — | — | 7,577,000Source | 18,814,000Source | 9,118,000Source | 9,171,000Source | 7,722,000Source | 12,228,000Source | 36,835,000Source | 66,102,000Source | 102,585,000Source | 136,489,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 188,000Source | 1,219,000Source | 319,000Source | -318,000Source | 113,000Source | 1,197,000Source | 1,182,000Source | 4,125,000Source | 14,349,000Source | 134,479,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | 1,000,000Source | 400,000Source | 1,500,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 10,360,000Source | 0Source | 0Source | 42,000,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 1,694,000Source | 16,000Source | 1,000Source |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 53,737,000Source | 0Source | 1,156,000Source | 3,208,000Source |
| Operating Income (Loss)USD | — | — | -7,577,000Source | -18,814,000Source | -9,118,000Source | -9,171,000Source | -7,722,000Source | -12,228,000Source | 16,902,000Source | -66,102,000Source | -101,429,000Source | -133,281,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 188,000Source | 1,219,000Source | 319,000Source | -318,000Source | 113,000Source | 1,197,000Source | 1,182,000Source | 4,125,000Source | 14,349,000Source | 134,479,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -87,080,000Source | 1,198,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 21,000Source | 0Source | 715,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,389,000Source | -17,595,000Source | -8,946,000Source | -9,489,000Source | -7,609,000Source | -11,031,000Source | 29,821,000Source | -47,733,000Source | -112,961,000Source | -5,005,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.6Source | -1.46Source | -0.44Source | -0.78Source | -0.54Source | -0.9Source | 2.42Source | -5.12Source | -1.95Source | -0.09Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.6Source | -1.46Source | -0.44Source | -0.78Source | -0.54Source | -0.9Source | 2.42Source | -6.58Source | -1.95Source | -0.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 12,240,542Source | 12,076,412Source | 20,342,345Source | 12,197,615Source | 14,095,371Source | 12,197,615Source | 12,300,568Source | 9,320,884Source | 57,834,819Source | 57,399,762Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 12,240,542Source | 12,076,412Source | 20,342,345Source | 12,197,615Source | 14,095,371Source | 12,197,615Source | 12,314,796Source | 9,657,696Source | 57,834,819Source | 57,399,762Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,022,000Source | 4,468,000Source | 4,859,000Source | 4,010,000Source | 4,504,000Source | 5,104,000Source | 17,679,000Source | 17,959,000Source | 31,256,000Source | 38,138,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 29,843,000Source | -47,716,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -1,625,000Source | — | — |
| Interest Income (Expense), NetUSD | — | — | -220,000Source | -917,000Source | -246,000Source | -284,000Source | -192,000Source | -371,000Source | 1,055,000Source | 2,832,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,389,000Source | -17,595,000Source | -8,946,000Source | -9,489,000Source | -7,609,000Source | -11,031,000Source | 29,821Source | -47,733Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 188,000Source | 1,219,000Source | 172,000Source | -318,000Source | 113,000Source | 1,197,000Source | 12,919,000Source | 20,015,000Source | — | — |
| Operating ExpensesUSD | — | — | 7,577,000Source | 18,814,000Source | 9,118,000Source | 9,171,000Source | 7,722,000Source | 12,228,000Source | 36,835,000Source | 66,102,000Source | 102,585,000Source | 136,489,000Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | 1,000,000Source | 400,000Source | 1,500,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 3,555,000Source | 14,346,000Source | 4,259,000Source | 5,161,000Source | 3,218,000Source | 7,124,000Source | 19,156,000Source | 48,143,000Source | 62,002,000Source | 98,351,000Source |
| Total Revenue | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-297538
Registration 333-297027
Filing attachments
d13352dex991.htm · 8-K · 2026-09-30
Exhibit 99.1 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 - Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 - - Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing - - Mechan…
Read attachment ↗d158730dex991.htm · 8-K · 2026-09-14
EX-99.1 2 d158730dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Q32 Bio Appoints José Trevejo, M.D., Ph. D., as Chief Medical Officer and Ellie Hershberger, Pharm. D., as Chief Development Officer - Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development - - Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory stra…
Read attachment ↗qttb-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 qttb-ex99_1.htm EX-99.1 EX-99.1 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed…
Read attachment ↗d150730dex41.htm · 8-K · 2026-07-15
EX-4.1 3 d150730dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK Q32 BIO INC. Warrant Shares: [___] Original Issuance Date: July [16], 2026 ────────────────────────────────────────────────────────────────────── Warrant No. 2026-PF-0[ ] THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [___] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitatio…
Read attachment ↗d143274dex991.htm · 8-K · 2026-07-13
EX-99.1 2 d143274dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SIGNAL-AA Part B 36-Week Topline Results July 2026 Forward Looking Statements This presentation has been prepared by Q32 Bio Inc. (“we”, “us,” “our,” “Q32” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and t…
Read attachment ↗d142528dex991.htm · 8-K · 2026-07-13
EX-99.1 2 d142528dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata - Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis - - 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at…
Read attachment ↗